Navigation Links
Doubt Cast on Use of Genetic Test Before Plavix
Date:12/28/2011

WEDNESDAY, Dec. 28 (HealthDay News) -- A new review of existing research suggests that, despite a federal recommendation, genetic testing won't help physicians determine which heart patients should get Plavix, a blood-thinning drug used to treat certain cardiac conditions.

Plavix, also known as clopidogrel, is used to treat or prevent blood clots due to the clogging of arteries and after such surgical procedures as balloon angioplasty.

But some patients won't experience the drug's clot-preventing benefits if their bodies don't process it properly, potentially leading to heart attack, blood clots in stents and death, according to Dr. Jean-Sebastien Hulot, associate professor of medicine at the Cardiovascular Research Center at Mount Sinai School of Medicine. Or, he said, they could experience the reverse -- excessive bleeding if the medication has too much of an effect. Hulot was not involved with the study, but is familiar with the findings.

The U.S. Food and Drug Administration believes that genetic testing could help identify patients who won't respond well to the drug. But the American Heart Association and the American College of Cardiologists have been skeptical that the genetic testing in question is useful.

In the new review, Dr. Michael V. Holmes of University College London and colleagues examined 32 studies that included over 42,000 patients. They looked for signs of bleeding problems, blood clots in stents and cardiovascular problems.

They also conducted a meta-analysis in which they examined statistics in the studies as a whole.

While they mention some statistical caveats, the researchers found that a specific genetic trait -- linked to the body's ability to respond to the drug -- did not significantly affect the risk of cardiovascular problems.

In a commentary accompanying the study, Dr. Steven E. Nissen, borrowing a phrase from a former chairman of the Federal Reserve, wrote, "It now appears that the FDA warning reflected a case of 'irrational exuberance.'"

Nissen, chair of cardiovascular medicine at the Cleveland Clinic, noted that the review has limitations. But, he added, for the time being physicians should "rarely, if ever" use the genetic testing in question and should "interpret the results with caution."

Hulot, the Mount Sinai School of Medicine professor, is skeptical. He said the findings are "far from convincing" and questioned their statistical validity. He also pointed to an earlier study, also a meta-analysis, that suggested a genetic trait did indeed boost the risk of problems for those who took the drug in certain cases.

The study is published in the Dec. 28 issue of the Journal of the American Medical Association.

More information

For more on Plavix (clopidogrel), visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Jean-Sebastien Hulot, M.D., Ph.D., associate professor of medicine and director, Pharmacogenomics & Personalized Therapeutics, Cardiovascular Research Center, Mount Sinai School of Medicine, New York City; Dec. 28, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia
2. Lifesaving antibiotics face doubtful future
3. Intensive care nurses have doubts about method for establishing brain death
4. New Report Casts More Doubt on Virus Link to Chronic Fatigue Syndrome
5. Study Casts Doubt on Hot Dogs Link to Colon Cancer
6. Requests for Alzheimers disease research grants up by 33 percent, as federal funding in doubt
7. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
8. Obstructive Sleep Apnea in Kids May Have Genetic Cause
9. Epigenetic signals differ across alleles
10. Study reveals genetic link between mammographic density and breast cancer
11. Genetic Risk Score Doesnt Spot Heart Trouble in Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Doubt Cast on Use of Genetic Test Before Plavix
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: